Alimera Sciences

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 20, 2024
Patient, Employment, Compensated emancipation, Alimera Sciences, Physician, Person, Pharmaceutical industry

The Compensation Committee approved granting on March 11, 2024, as an inducement material to each new employee’s employment, 125,000 restricted stock units and 125,000 performance-based restricted stock units to Mr. Wood; 75,000 restricted stock units and 75,000 performance-based restricted stock units to Mr. Maltz; and options to collectively purchase up to 24,500 shares of common stock of the Company to the five other new, non-executive employees.

Key Points: 
  • The Compensation Committee approved granting on March 11, 2024, as an inducement material to each new employee’s employment, 125,000 restricted stock units and 125,000 performance-based restricted stock units to Mr. Wood; 75,000 restricted stock units and 75,000 performance-based restricted stock units to Mr. Maltz; and options to collectively purchase up to 24,500 shares of common stock of the Company to the five other new, non-executive employees.
  • The stock options have an exercise price of $3.77 per share, which is equal to the closing price of a share of the Company’s common stock on the Nasdaq Global Market on March 11, 2024.
  • One third (1/3) of the performance-based restricted stock unit awards will vest annually during a three-year performance period if either one of the pre-established annual revenue target or stock price target is satisfied during such performance year, subject to continued employment with the Company through the vesting dates.
  • Each Inducement Grant was awarded as an inducement material to the employee’s commencement of employment in accordance with Nasdaq Listing Rule 5635(c)(4), and each such Inducement Grant Each award is subject to the terms and conditions of the Alimera Sciences, Inc. 2024 Equity Inducement Plan and the grant agreements evidencing the awards.

Repligen Appoints Maggie A. Pax to Board of Directors

Retrieved on: 
Tuesday, March 19, 2024
College, Innovation, Growth, Life Technologies, Repligen, Business, MIT, Thermo Fisher Scientific, Harvard Business School, Strategic planning, Business development, Acquisition, Massachusetts Institute of Technology, MBA, Marketing, Holy Cross, Alimera Sciences, Corporation, Management

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax.

Key Points: 
  • WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax.
  • Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies.
  • Karen A. Dawes, Chairperson of the Board of Directors for Repligen, said, “We’re very happy to welcome Maggie Pax as a terrific addition to the Repligen Board with extensive experience in the life sciences industry.
  • Hunt, Chief Executive Officer for Repligen said, “Maggie understands first-hand the drivers of growth for our industry and has touched many of the focus areas for Repligen: key account programs, continuous innovation and M&A integration.

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

Retrieved on: 
Tuesday, March 19, 2024
Macular edema, Fluocinolone acetonide, Observation, Intravitreal implants, Injection, Risk, Paratriathlon, Patient, Alimera Sciences, Plaque, Cleveland Clinic, Retina, Brachytherapy, Radiation, Physician

ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the first patient has been randomized in the DRCR Retina Network’s Protocol AL. The study is titled, “A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy.”

Key Points: 
  • ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the first patient has been randomized in the DRCR Retina Network’s Protocol AL.
  • The study is titled, “A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy.”
    The study, chaired by Arun Singh, M.D.
  • (Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio), plans to include 600 participants with primary choroidal melanoma receiving treatment with plaque brachytherapy.
  • “We are very excited that this study is underway as it has the potential to show ILUVIEN addressing another unmet need affecting the retina,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.

Luckie & Company Acquires Marbury Creative Group

Retrieved on: 
Tuesday, April 2, 2024
Growth, Partnership, Alimera Sciences, Acquisition, Food, Senior, Spice World, Owens & Minor, Marketing, Advertising, MCG, Sales

ATLANTA and BIRMINGHAM, Ala., April 2, 2024 /PRNewswire/ -- Luckie & Company announces  the acquisition of Marbury Creative Group (MCG), an Atlanta-based creative marketing agency recognized for its work in the pharmaceutical, food & beverage, and hospitality industries.

Key Points: 
  • ATLANTA and BIRMINGHAM, Ala., April 2, 2024 /PRNewswire/ -- Luckie & Company announces  the acquisition of Marbury Creative Group (MCG), an Atlanta-based creative marketing agency recognized for its work in the pharmaceutical, food & beverage, and hospitality industries.
  • Marketing and advertising agency, Luckie & Company, expands with acquisition of Marbury Creative Group.
  • The acquisition brings Luckie expansion in critical areas, including content, search engine marketing, media strategy & planning, plus a seasoned team focused on creative, strategy, and media.
  • Marbury will be an Executive Creative Director at Luckie.

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 7, 2024
CFO, EDT, Acquisition, Total, Injection, Trosia, Investment, Physician, Inflammation, Growth, Eye, Adjustment, Conference, Safety, Alimera Sciences, Depreciation, Patient, Tax, SLR, DME, Macular edema, Video game

ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the fourth quarter and full year 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

Key Points: 
  • Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
  • “We are proud to have achieved positive Adjusted EBITDA during the fourth quarter of 2023, while maintaining a consistent net loss compared to the fourth quarter of 2022, despite facing greater interest and amortization expenses following the YUTIQ acquisition.
  • For 2023, international net revenue increased 21% to approximately $24.0 million for 2023, compared to approximately $19.9 million in 2022.
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update

Retrieved on: 
Thursday, February 29, 2024
Physician, Internet access, Alimera Sciences, Trosia, Patient

Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.

Key Points: 
  • Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.
  • Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay.
  • Those without Internet access or who are unable to pre-register may dial in by calling 1-844-839-2190 (domestic) or 1-412-717-9583 (international).
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®

Retrieved on: 
Thursday, February 8, 2024
Alimera Sciences, Visual impairment, NHS Wales, News, Patient, Recurrence, Physician, NHS, Disease, Fluocinolone acetonide, DME, NHS England, Pharmaceutical industry

“This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.

Key Points: 
  • “This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.
  • We look forward to the publication of Final Guidance shortly.”
    NICE is recommending on label access to ILUVIEN as an option for treating visual impairment caused by chronic DME in phakic eyes.
  • NHS England has agreed with the Integrated Care Boards (ICB’s) to provide funding to implement this guidance 30 days after publication.
  • NHS Wales will usually fund within 2 months of the final draft guidance.

Alimera Completes Recruitment for the Synchronicity Study

Retrieved on: 
Thursday, January 4, 2024
Alimera Sciences, Fluocinolone acetonide, Physician, Acquisition, Inflammation, NIU, Patient, Safety, Retina, Pharmaceutical industry

ATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that it has completed enrollment for the company’s Synchronicity Study, a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ (fluocinolone acetonide intravitreal implant 0.18mg) in the treatment of chronic non-infectious uveitis and related intraocular inflammation.

Key Points: 
  • ATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that it has completed enrollment for the company’s Synchronicity Study, a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ (fluocinolone acetonide intravitreal implant 0.18mg) in the treatment of chronic non-infectious uveitis and related intraocular inflammation.
  • “We are pleased to reach the enrollment target for this Phase 4 open-label study only a few short months after our acquisition of YUTIQ,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer.
  • “We look forward to the initial readout from this study in the second half of next year to provide retina specialists with a broader sense of the utility of fluocinolone acetonide in a durable intravitreal implant across a variety of patients with chronic non-infectious uveitis affecting the posterior segment (NIU-PS).
  • This could potentially benefit both YUTIQ in the United States and ILUVIEN in Europe and the Middle East, where it is approved to treat chronic NIU-PS.”

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, January 2, 2024
Gelesis, Alimera Sciences, Bookkeeping, CFO, Physician, International, Elon University, Growth, Patient, Compensated emancipation, Therapy, Employment, Retina, Trosia

“Elliot joins the Alimera leadership team at an exciting time as we enter 2024 preparing to enhance our growth trajectory and drive improved cash flow,” said Rick Eiswirth, Alimera’s President and CEO.

Key Points: 
  • “Elliot joins the Alimera leadership team at an exciting time as we enter 2024 preparing to enhance our growth trajectory and drive improved cash flow,” said Rick Eiswirth, Alimera’s President and CEO.
  • Most recently he was the Chief Financial Officer with Orgenesis, Inc., a publicly traded global biotech company transforming the processing of cell and gene therapies.
  • At Gelesis, Mr. Maltz advanced from Corporate Controller to Vice President of Finance and then to Chief Financial Officer while leading numerous operational and fundraising initiatives.
  • The Inducement Option is an inducement material to Mr. Maltz entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, December 12, 2023
Marketing, Alimera Sciences, Dermatology, Uveitis, Physician, Weight loss, Optometry, Injection, Recurrence, Allergan, Genomics, Patient, Grand Valley State University, Compensated emancipation, Employment, AbbVie, Pharmaceutical industry

Sales, Eye Care, Area Director, Facial Aesthetics and Senior Product Manager, Lumigan (glaucoma product).

Key Points: 
  • Sales, Eye Care, Area Director, Facial Aesthetics and Senior Product Manager, Lumigan (glaucoma product).
  • He most recently served as Chief Commercial Officer at Dermtech International, a leading genomics company in dermatology.
  • in business administration from Grand Valley State University, Allendale, Mich.
    “I’m looking forward to building upon Alimera’s strong foundation to establish a program for long-term success,” said Mr. Wood.
  • The Inducement Option is an inducement material to Mr. Wood entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).